The result of the consolidated entity has increased from a loss of $(3,093,163) in the year ended 30 June 2016 to a loss of $(4,090,257). This is primarily due to the cost of running the Phase IIb clinical trial of NTCELL in Parkinson’s disease and the cost of manufacturing NTCELL for the trial. Cash and cash equivalents has increased from $5,301,999 to $7,530,033 due to a private placement to institutional and professional investors in November 2016 raising net $5.9m, partially offset by NTCELL manufacturing, clinical trial costs and ongoing corporate expenses.
Not too shabby
Ann: Preliminary Final Report and Financial Statements, page-2
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $2.645K | 331.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 6065873 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1680539 | 10 |
View Market Depth
| Last trade - 15.55pm 16/08/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |